DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2<sup>+</sup> breast cancer
Our study revealed novel functions of DLL4 in cell stemness and immune infiltration, including NET formation and T cell exclusion, which collectively contributed to THP neoadjuvant therapy resistance in HER2<sup>+</sup> BC. Furthermore, we provided a CAR-T-based therapy to sensitize the THP neoadjuvant therapy.
Authors
- Jingrui Yan
- Yongjie Xie
- Ziyun Liu (ORCID: https://orcid.org/0000-0003-2992-7590)
- Tianxing Zhou (ORCID: https://orcid.org/0009-0006-0150-1343)
- Yanfang Yang (ORCID: https://orcid.org/0000-0002-0981-8904)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-009636
- Citations
- 8
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 2.26